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40% of that population. This raises a serious question about
proceeding to transplantation in the first year of the disease, as four
centers have advised on the basis of their perception that DCM
had such a poor prognosis. In this published cohort, some
recovered as late as six years after onset; would 40% of the
transplanted children have recovered with normal contractility had
they not been transplanted?
Although the title of their study asserts that transplantation for
DCM will provide “improved outcomes,” that can only apply to
the first few years after cardiac transplantation, which lasts on
average 10 to 13 years. In contrast, 40% of all patients with DCM
recovered systolic function without transplantation and were still
normal eight years later. The difference between transplants and
complete recovery does not take into account the morbidity of
rejections and anti-immune treatments for the transplanted pa-
tients. If 40% of the transplanted children would have recovered,
the overall outcome would certainly not be improved.
Finally, the reliability of separating myocarditis from idiopathic
DCM is raised by their finding of no differences between the two
groups for either “heart death” or for recovery of function. This
important finding throws doubt on the criteria used to diagnose
myocarditis.
In sum, this important study by Tsirka et al. (1) provided several
important advances in our knowledge, even though the title made
promises that were unwarranted.
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REPLY
We appreciate Dr. Guntheroth’s remarks regarding our retrospec-
tive observational study (1) on pediatric dilated cardiomyopathy
(DCM). His concerns appropriately point out the limitation of all
observational studies—that one can never tell what would have
happened to the treated group (in this case those who were
transplanted) had they not undergone treatment because there is
no valid comparison group. However, 75% of the patients trans-
planted in our study were on persistent inotropic support (UNOS
status 1) at the time of transplant and had failed attempts to
remove inotropic support. Data from the Pediatric Heart Trans-
plant Study (PHTS) (2) suggest that inotropic support is a risk
factor for death before transplant. Thus, we believe our patients
who underwent transplantation represented a substantially sicker
subgroup of patients within the patient population studied. How-
ever, newer heart failure therapies such as beta-blockade have been
reported to remove the survival advantage from heart transplanta-
tion in adults (3) and to decrease utilization of heart transplanta-
tion in infants and children (4). The role of heart transplantation
as therapy for pediatric DCM needs to be continually redefined as
newer heart failure therapies are applied to pediatric heart disease.
Dr. Guntheroth suggests that inclusion of patients with DCM
from metabolic disease or muscular dystrophy may be misleading
because of the uniformly fatal nature of those diseases. The
differing natural history of the Becker and Duchenne variants of
dystrophin muscular dystrophy underscores the difficulties of
lumping all metabolic cardiomyopathies and muscular dystrophies
in one common prognostic group.
We would agree with Dr. Guntheroth that the criteria used in
our study to diagnose myocarditis are not clear cut. The frequency
of viral infection in children can make it likely that any diagnosis
of a DCM can generally correlate with a “recent” viral infection.
Pathologic criteria can also be confusing given the patchy nature of
myocardial inflammation leading to false negative endomyocardial
biopsies and the presence of viral genome in myocardial samples
without evidence of inflammation (5). Thus, any clear-cut defini-
tion of myocarditis in children remains difficult.
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Cell Transplantation and Fibrin Matrix
The recent study by Christman et al. (1) reports the results of an
experimental study that evaluated a “novel approach to heart repair
that uses an injectable biopolymer scaffold to deliver cells directly
into the infarct wall.” The researchers “hypothesized that the
injection of cells in a solution that becomes a semi-rigid scaffold
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